Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30+
SponsorUniversity of California, Los Angeles

About this trial

An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Stroke is defined as symptoms lasting >24 hours and associated with imaging evidence of acute ischemia in the distribution of the stenotic vessel on head CT or brain MRI. Minor stroke is defined as NIHSS<6, as used in prior studies.

Eligible TIA, defined as transient neurological symptoms lasting <24 hours, need to be: a) accompanied by DWI abnormalities in the distribution of the stenotic artery; or b) multiple (>1), stereotyped events associated with unequivocal ischemic symptoms (i.e. weakness, aphasia, diplopia), and attributed to the symptomatic artery. The intent of these restrictive inclusion criteria for TIA is to exclude potential stroke mimics.

ICAD should involve the intracranial carotid, middle cerebral, intracranial vertebral or basilar arteries. Isolated anterior and posterior cerebral artery stenosis is not included as it is uncommon in these locations and non-invasive criteria for high-grade ICAD are not well established for these vessels.

Stenosis 50-99% will be quantified by CTA. The criteria for 50-99% are: measured stenosis by WASID criteria (percent stenosis = (1-[diameter stenosis/diameter normal]) x 100%.

Disqualifiers

Other determined etiology or established cause of the acute stroke or TIA: atrial fibrillation, mitral stenosis, mechanical valve, intracardiac thrombus or vegetation, dilated cardiomyopathy or ejection fraction <30%, proximal extracranial carotid or vertebral stenosis >50%.

Contraindications to MRI, including MR-incompatible metallic implants (i.e. certain artificial cardiac valves, penile implants, other prosthesis), implanted electronic devices (i.e. pacemaker/defibrillator, neurostimulators, cochlear implants), other potentially mobile ferromagnetic material (i.e. shrapnel, magnetic aneurysm clips), pregnancy (women in fertile age should have a negative pregnancy test), lactation, morbid obesity, and severe claustrophobia.

Trial population

Individuals with who have experience a Stroke or TIA

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Medical Imaging

    Diagnostic test

    magnetic resonance imaging

Treatment groups

250 Participants
are divided into 1 treatment group
Group A: All1 intervention

Trial outcomes

Primary outcomes

1

Determine the impact of platelet FcγRIIa expression on 1-year risk of recurrent stroke in ICAD.

The investigators hypothesize that increased platelet FcγRIIa will be associated with a greater risk of ischemic events. Platelet FcγRIIa expression will be quantified in 250 subjects enrolled at 6 sites with stroke or TIA due to 50-99% ICAD to determine impact of FcγRIIa on 1-year risk of recurrent stroke, including clinical events and serial MRI.

Time frame
1 year
2

Quantify the impact of WSS from CTA CFD on 1-year risk of recurrent stroke in ICAD

The investigators hypothesize that high WSS and an elevated post-stenotic oscillatory shear index (OSI) that are stimuli of shear-induced platelet aggregation will confer an increased risk of recurrent ischemic stroke. We will use routinely acquired CTA in 250 subjects enrolled at 6 sites with stroke or TIA due to 50-99% ICAD to quantify the impact of WSS and post-stenotic OSI on 1-year risk of recurrent stroke, including clinical events and serial MRI.

Time frame
1 year
3

Develop a precision model to determine the risk of recurrent stroke 1 year after index events due to ICAD based on individual FcγRIIa expression and WSS from baseline CTA.

The investigators hypothesize that the 1-year recurrent stroke risk associated with high platelet FcγRIIa expression and high WSS will be more than additive.

Time frame
1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of California, Los Angeles

Lead sponsor

University of Pittsburgh Medical Center

Collaborator

University of Chicago

Collaborator

Bay State Clinical Trials, Inc.

Collaborator

Yale University

Collaborator

University of Vermont

Collaborator

University of Southern California

Collaborator